Clinical Trials Logo

Epilepsy, Generalized clinical trials

View clinical trials related to Epilepsy, Generalized.

Filter by:

NCT ID: NCT06388174 Recruiting - Epilepsy Clinical Trials

Idiopathic Generalized Epilepsy Syndromes

Start date: January 1, 2023
Phase:
Study type: Observational

The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance. According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

NCT ID: NCT06194422 Not yet recruiting - Clinical trials for Psychiatric Comorbidities

Psychiatric Comorbidities in Children With Generalized Epilepsy

Start date: December 30, 2023
Phase:
Study type: Observational

Epilepsy is defined as a chronic disorder that presents with recurrent episodes of unprovoked seizures. Epileptic seizures are caused by excessive excitation of cortical neurons. The condition has various etiologies and comorbidities. Classification; The Classification of Epilepsies includes several diagnostic levels (steps): 1. from seizure type to epilepsy type (generalized/focal/combined generalized and focal/unknown) 2. etiology (genetic/ structural/ infectious/ metabolic/ immune/unknown). A clinician can use any level of the classification

NCT ID: NCT05530109 Recruiting - Clinical trials for Idiopathic Generalized Epilepsy

Study of Attentional Disorders in Patients Suffering From Idiopathic Generalized Epilepsy.

ATTENTIONEPIG
Start date: April 26, 2022
Phase:
Study type: Observational

Attentional disorders have been reported in neuropsychological studies evaluating patients suffering from generalized idiopathic epilepsy, but the data are disparate (in terms of test protocol). We aim to describe attentional and executive function disorder in IGE thanks to the Epitrack scale, validated in this specific population. Our secondary objective is to study the dynamic of cortical activity during an attentional task (the ANT), in order to describe the alteration of cortical networks in epileptic patients presenting with attentional disturbance.

NCT ID: NCT05477121 Recruiting - Clinical trials for Epilepsy, Generalized

Severity: Quantifying the Severity of Generalized Tonic-clonic Seizures (GTCS) With Connected Devices

Start date: June 12, 2019
Phase:
Study type: Observational

By bringing together the fields of seizure detection and that of Sudden Unexpected Death in Epilepsy (SUDEP), the current project aims at delineating which set of biosensors and related biomarkers would optimally characterize the severity of GTCS and the associated risk of SUDEP.

NCT ID: NCT05374928 Recruiting - Clinical trials for Idiopathic Generalized Epilepsy

Human Epilepsy Project 3

HEP3
Start date: March 9, 2020
Phase:
Study type: Observational

By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to make more informed decisions about the factors affecting their quality of life, including plans for driving, relationships, pregnancy, schooling, work, and play. In addition to its impact on clinical care, the data and specimens collected in HEP3, including sequential electrophysiology, biochemical profiles and neuroimaging and banked DNA for future genomics studies, have the potential to provide new insights into the biological basis of IGE, thereby advancing the discovery of effective treatments and cures. By enrolling both newly diagnosed subjects (prognosis unknown) as well as subjects with established IGE who are already determined to be treatment resistant or treatment responsive, the study team can immediately test potential biomarkers in a confirmation cohort, which will accelerate identification of predictive biomarkers.

NCT ID: NCT05297695 Completed - Clinical trials for Helicobacter Pylori Infection

Helicobacter Pylori Eradication Therapy for Epileptic Children

Start date: April 20, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Helicobacter pylori (H. pylori) infection is associated with several health problems. The role of H. pylori infection in epilepsy has been investigated in a few studies. To the best of our knowledge, there have been no previous studies on the effect of treating H. pylori infection on seizure frequency among children with drug-resistant idiopathic generalized epilepsy. This study aims to evaluate the effect of treating H. pylori infection on seizure frequency among children with drug-resistant idiopathic generalized epilepsy.

NCT ID: NCT05241678 Completed - Clinical trials for Epilepsy, Generalized

Evaluation of the 24/7 EEG™ SubQ System in Subjects With Uncontrolled Genetic Generalised Epilepsy Syndrome

Start date: February 15, 2022
Phase:
Study type: Observational [Patient Registry]

This study is a 12 week prospective, comparative investigation in subjects diagnosed with uncontrolled genetic generalised epilepsy (GGE) also known as idiopathic generalised epilepsy (IGE). The purpose of the study is to evaluate whether the 24/7 EEG™ SubQ system, a subcutaneous implantable device, will demonstrate seizure sensitivity approximating that of inpatient video-EEG monitoring with the standard 10-20 electrode system.

NCT ID: NCT05147571 Active, not recruiting - Epilepsy Clinical Trials

RNS System NAUTILUS Study

NAUTILUS
Start date: August 9, 2022
Phase: Phase 3
Study type: Interventional

To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.

NCT ID: NCT04965571 Completed - Wilson Disease Clinical Trials

Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients

Start date: September 1, 2010
Phase:
Study type: Observational

Generalized epilepsy is rarely reported in patients with Wilson disease (WD) and lacks experience in clinical practice. We aim to provide better experience for the diagnosis and treatment for WD patients with epilepsy in the future.

NCT ID: NCT04959019 Recruiting - Memory Impairment Clinical Trials

Exercise for Memory Rehabilitation in Epilepsy

Start date: July 21, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how effective a 6-week exercise program is for improving memory compared to a no-intervention control group, investigate the brain changes that may be responsible for memory improvements, and determine if the memory benefits and brain changes are retained 6 weeks after completing the exercise intervention in people with Idiopathic generalized epilepsy (IGE).